BioSpace News Archive

FIGS, Inc. (NYSE: FIGS), the direct-to-consumer healthcare apparel and lifestyle brand, and Eko Health, Inc. (“Eko”), a leading innovator in digital health technology for heart and lung disease detection, today announced the launch of the FIGS | Eko CORE 500™ Digital Stethoscope.

Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, today announced that Meesha Dogan, Ph.D., CEO of Cardio Diagnostics, will present at the following investor conferences.

Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), (“Biophytis” or the “Company”) announces that its CEO, Stanislas Veillet, will participate and hold a presentation at the “H.C. Wainwright 25th Annual Global Investment Conference”, which takes place from September 11 to 13, 2023 in New York.

Breathe BioMedical has announced Bill Dawes as their new Chief Executive Officer, effective August 14, 2023.

IQVIA Holdings Inc., announced that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Baird 2023 Global Healthcare Conference in New York City on Wednesday, September 13, 2023 at 10:50 a.m. ET.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, Sept. 11, 2023 at 8:40 a.m. E.T.

Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced that it will be participating in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 at the Lotte New York Palace Hotel in New York City.

Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today announced it shared an encore poster presentation at the 10th annual Metastatic Breast Cancer Research Conference (MBCRC) highlighting the results of its Phase 2 ELAINE-2 clinical study.

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate in the following upcoming investor conferences in September.

Alvotech announced that Faysal Kalmoua has been appointed Alvotech’s Chief Operating Officer and Hafrun Fridriksdottir is stepping down following resubmission of the Biologics License Application for AVT02, Alvotech’s proposed high-concentration interchangeable biosimilar to Humira®.